Optimizing tuberculosis treatment efficacy: Comparing the standard regimen with Moxifloxacin-containing regimens
Fig 2
Comparison of moxifloxacin–containing regimens to the standard regimen for the human study and GranSim.
(A) Results from the REMoxTB clinical trial [33]. Probability that a patient has a sputum culture–positive status decreases over the course of treatment, and this decline is more pronounced for moxifloxacin–containing regimens. Control (HRZE), HRZM and RMZE groups have 510, 514 and 524 patients, respectively. This figure is adapted from Fig 2B of [33] (Data points (x) extracted by WebPlotDigitizer). (B,C) GranSim predictions for (B) the fraction of unsterilized granulomas and (C) sterilization times upon treatment with HRZE, HRZM and RMZE (*p<0.001, one–tailed paired t–test). The central red lines in box plots represent the median, whereas the bottom and the top edges of boxes represent 25th and 75th percentiles, respectively. For the REMoxTB study and the simulations, in the control groups, patients/granulomas are treated with HRZE for 8 weeks, followed by an 18–week long HR treatment. In HRZM and RMZE groups, patients/granulomas are treated with HRZM and RMZE for 17 weeks, respectively (see Methods and Table 1). In (B) and (C), each group has 200 simulated granulomas.